Research profile
Mitochondrial membrane biology
Disease-specific clinical development
What it is and why it is studied
SS-31, also known as elamipretide, is a modified four-residue peptide. SS-31 research centres on mitochondria and the consequences of impaired cellular energy production. Studies of elamipretide investigate how this research translates into physical function in people with defined mitochondrial disorders.
What studies have found
The phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet its primary walking-distance or fatigue endpoints. Separately, a medicinal elamipretide product received US accelerated approval for a specific Barth syndrome indication in September 2025.
Disease-specific evidence and approval of a defined medicine do not establish general energy, anti-ageing or personal-use benefits for this research vial.
Read the research
Chemical reference
| Reference sequence | H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2 |
|---|---|
| Molecular formula | C32H49N9O5 |
| Molar mass | Approximately 639.8 g/mol |
| Reference CAS | 736992-21-5 |
| PubChem CID | 11764719 |
Elamipretide is also known as SS-31. Its reference sequence includes D-arginine, 2,6-dimethyltyrosine and a C-terminal amide.
Chemical information describes the named reference structure, not a batch analysis or confirmation of the material supplied. Counterions, water and excipients are excluded unless stated.
Understanding these details
A sequence describes the order of residues in a peptide. A molecular formula describes the atoms in the reference structure. Molar mass is expressed in grams per mole; it is not the amount in a vial. CAS numbers and PubChem identifiers help you find the corresponding chemical records.
Selected literature and reference information checked 11 September 2026. Study findings concern the preparations and models described; they do not certify this product. For laboratory research only.
Reviews
There are no reviews yet.